Robert Malanuk, MD
Interventional Cardiology · West Columbia, SCNPI 1740242304
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 57.8% of the total. 2025 is the largest year on record at $7,695, 4.3 times the $1,785 reported in 2019.
Across 778 payments — averaging $32.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$15K
- Novartis$1K
- Boston Scientific$1K
- Amgen$896
- Medtronic$817
- Pfizer$740
- plus $6K from 41 others
Across 49 payments — averaging $762.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$27K
- Abbott$8K
- Biotronik Inc.$2K
What the payments were for
- Consulting fees$9004%
- Speaking & faculty fees$12,35949%
- Food & beverage$12,08348%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,406 in reported general payments places this provider in the 80th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,199 | $1,197,112 |
| EntrestoSacubitril/Valsartan | 329 | $344,688 |
| XareltoRivaroxaban | 147 | $146,794 |
| Repatha SureclickEvolocumab | 128 | $113,774 |
| FarxigaDapagliflozin Propanediol | 119 | $98,521 |
| JardianceEmpagliflozin | 37 | $46,147 |
| MultaqDronedarone Hcl | 20 | $25,848 |
| BrilintaTicagrelor | 44 | $19,374 |
| Praluent PenAlirocumab | 27 | $19,022 |
| Metoprolol Succinate | 1,003 | $16,918 |
| Atorvastatin Calcium | 847 | $13,284 |
| Rosuvastatin Calcium | 391 | $9,264 |
| Ezetimibe | 260 | $9,209 |
| Ranolazine ErRanolazine | 93 | $8,263 |
| VascepaIcosapent Ethyl | 15 | $7,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $740 | $1,197,1121,199 claims |
| NovartisEntresto | $1,319 | $344,688329 claims |
| Johnson & JohnsonXarelto | $235 | $146,794147 claims |
| AstraZenecaFarxiga, Brilinta | $394 | $117,896163 claims |
| Boehringer IngelheimJardiance | $191 | $46,14737 claims |
| Sanofi-aventis U.S. LLCMultaq | $328 | $25,84820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in West Columbia
- Robert LeonardiWest Columbia$203K
- Christopher PerryWest Columbia$26K
- Gregory GiuglianoWest Columbia$25K
- Garrett RuthWest Columbia$14K
- Jonathan HewettWest Columbia$11K
- Brandon DraftsWest Columbia$11K
- William BrearleyWest Columbia$10K
- Brian WallWest Columbia$10K
- Daniel SteinbergCharleston$611K
- Brian BrownSpartanburg$389K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.